Skip to main
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics is a clinical-stage biopharmaceutical company that has recently reported its Q2 FY26 results, showing a lower-than-expected revenue of $0.1 million and an EPS of $(0.16). Despite this, they have received marketing authorization for their ophthalmic formulation of ONS-5010/LYTENAVA and have significant upside potential as they are expecting FDA approval within the next 60 days for their main therapeutic candidate. Additionally, their LYTENAVA product has potential pricing and reimbursement advantages, making it a strong competitor in the market.

Bears say

Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, for various ophthalmic indications. While the company recently received marketing authorization for ONS-5010/LYTENAVA in the EU and UK, with plans for additional launches in other European countries, there are significant risks involved, including balance sheet and liquidity risks, potential competition, and the need for product candidates to demonstrate safety and efficacy in clinical trials. While there is potential for significant growth and upside opportunities, these risks warrant a negative outlook on the company's stock.

OTLK has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 3 analysts, OTLK has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.